Wave Life Sciences (WVE) Enterprise Value (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Enterprise Value came in at -$368.0 million in Q2 2026, down 76.5% YoY from -$1.6 billion in Q2 2025, and up 32.43% on a QoQ basis from -$544.6 million in Q1 2026.
Wave Life Sciences (WVE) Enterprise Value (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Enterprise Value data on file, last reported at -$368.0 million in Q2 2026.
- Quarterly Enterprise Value fell 76.5% year-over-year to -$368.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$368.0 million (down 76.5% YoY) and the FY2025 annual result came in at -$602.1 million, down 99.31% from the prior year.
- Enterprise Value climbed to -$368.0 million in Q2 2026, from -$544.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$88.5 million in Q4 2022 to a low of -$602.1 million in Q4 2025.
- A 5-year average of -$244.5 million and a median of -$198.3 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 41.22% — and 2023, when it sank 126.39%.
- Tracing WVE's Enterprise Value over 5 years: stood at -$88.5 million in 2022, then tumbled by 126.39% to -$200.4 million in 2023, then sank by 50.77% to -$302.1 million in 2024, then sank by 99.31% to -$602.1 million in 2025, then surged by 38.88% to -$368.0 million in 2026.
- The last three Enterprise Value figures came in at -$368.0 million (Q2 2026), -$544.6 million (Q1 2026), and -$602.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | -368.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -368.01 Mn |
| Mar 31, 2026 | -544.59 Mn |
| Dec 31, 2025 | -602.07 Mn |
| Sep 30, 2025 | -196.20 Mn |
| Jun 30, 2025 | -208.48 Mn |
| Mar 31, 2025 | -243.10 Mn |
| Dec 31, 2024 | -302.08 Mn |
| Sep 30, 2024 | -310.95 Mn |
| Jun 30, 2024 | -154.00 Mn |
| Mar 31, 2024 | -180.90 Mn |
| Dec 31, 2023 | -200.35 Mn |
| Sep 30, 2023 | -139.90 Mn |
| Jun 30, 2023 | -173.00 Mn |
| Mar 31, 2023 | -207.60 Mn |
| Dec 31, 2022 | -88.50 Mn |
| Sep 30, 2022 | -147.04 Mn |
| Jun 30, 2022 | -173.20 Mn |
| Mar 31, 2022 | -161.70 Mn |
| Dec 31, 2021 | -150.56 Mn |
| Sep 30, 2021 | -123.90 Mn |